Tip os
Log ind
POLFOTO_46554039.jpg
Foto: Philip Davali/Ritzau/arkiv

Bavarian to test cancer vaccine with Roche’s checkpoint inhibitor

Top picks in English:

Denmark-based biotech company Bavarian Nordic is expanding its clinical program for experimental cancer vaccine CV301, which is to be examined in combination with a checkpoint inhibitor from Roche.


BY STEFAN SINGH KAILAY
Offentliggjort 13.03.17 kl. 12:28

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Darzalex is still the “star of the show” for Genmab

JanVanDerWinkel01.JPG Top picks in English:

Genmab’s Darzalex royalties now cover the company’s operating costs and in addition to that, the cancer drug continues its expansion to new markets. And according to CEO, Jan van de Winkel, Genmab could potentially raise its guidance this year.

Novo will no longer offer price guidance

Top picks in English:

Novo Nordisk will no longer announce the expected price development for its products on the US market.

Novo expands its executive team

Top picks in English:

Novo Nordisk has promoted two of its regional directors to its executive management team, which has undergone a slew of changes in the past year.

Zealand carries out USD 89m IPO in the US

Top picks in English:

Zealand Pharma has listed on the Nasdaq Global Select Market in addition to its listing in Copenhagen, raising USD 89 in the process. But the move does not mean the biotech company has lost faith in the Danish investor base, says CEO Britt Meelby Jensen.

Kåre Schultz after guidance hike: Hard to gauge generic competition

Top picks in English:

The US competitor to Lundbeck’s epilepsy drug Sabril is long in coming and this is partly the reason behind the new guidance hike for the Danish company. In the first half year of 2017, Sabril continued to gain market shares in the US.

ALK CEO: We call the FDA on a daily basis

Top picks in English:

Denmark’s ALK is ready to go “full steam” in the launch of a promising tablet against house dust mite allergy on the US market as early as this year. The only obstacle is a formal handover of the marketing permit from former partner Merck, which could push the launch into 2018.

Forsiden lige nu

Opioid-producent ramt af nyt søgsmål

cb.jpg Medicinal & Biotek:

Den amerikanske delstat South Carolina er den seneste i rækken af stater og amter, der går rettens vej mod producenter af det smertestillende middel opioid.

Sydbank: Sonova-lancering er ingen revolution

Medico & Rehab:

Verdens største høreapparatproducent, schweiziske Sonova, præsenterede torsdag sin nye trådløse platform, der kan give en lille fordel i forhold til de danske konkurrenter GN Hearing og William Demant, mener Sydbank-analytiker Morten Imsgaard.

FDA godkender mange produkter på et tyndt grundlag

Medicinal & Biotek:

To nye studier peger på, at en lang række lægemidler og medicinsk udstyr godkendes til det amerikanske marked uden tilstrækkelige beviser for deres effekt og sikkerhed.

Britisk medicinalkoncern slagtet efter nedjustering

Medicinal & Biotek:

Investorerne har ikke behandlet Hikma Pharmaceuticals flinkt, efter medicinalkoncernen har leveret et skuffende regnskab torsdag.

GN: Bestyrelsesmedlem sælger aktier for 1,5 mio. kr. efter regnskab

Medico & Rehab:

Hos danske GN Group, med høreapparatdivisionen GN Hearing, har et bestyrelsesmedlem solgt 7448 aktier til en værdi af 1,5 mio. kr. torsdag.

Storbank: Semaglutid står over for stærk lancering

Medicinal & Biotek:

Nye opløftende fase 3-data får den svenske storbank til at spå en stærk lancering af Novo Nordisks nyeste diabetesmiddel, semaglutid, som kan blive godkendt i USA allerede i år.

ANNONCE
ANNONCE


ANNONCE